PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Transdermal Delivery Solutions Corporation (TDSC) www.TDSC.us announced today that transdermal delivery veteran Wallace K. “Wally” Reams has joined its Board of Advisors.
Reams (https://www.linkedin.com/in/wreams) led the acquisition of Aveva Drug Delivery Systems Inc., a Florida based developer and manufacturer of transdermal patches, for Nitto Denko Corporation, where as President and COO from 2003 -2014 he successfully launched products for pain management, hypertension, antiemesis (resulting from chemotherapy) and smoking cessation.
"We are very pleased to have Wally Reams, a veteran transdermal delivery industry professional, join our Board of Advisors. His years of experience as COO of Aveva, as well as his reputation, relationships and track-record of success in the pharmaceutical and medical device industries, will be an invaluable asset to our organization moving forward," said Kenneth Kirby, President of TDSC.
Mr. Reams has 30+ years of experience in the pharmaceutical (transdermal drug delivery), medical device (wound care) and industrial products areas. He has demonstrated success in start-up and turnaround, new business development, strategic alliance and development of high quality senior management teams. He has extensive international experience, managing a strategic alliance in Japan, global distribution and in his role of Directeur Général (President) of Brady SARL successfully led a turnaround and restructuring of a manufacturing and marketing company in Jouy-le-Potier, France.
“I am excited to join Ken and the TDSC team and look forward to helping move this paradigm-shifting platform technology to the market,” said Mr. Reams. “From my perspective of many years in development of patch-based transdermal delivery products, I can honestly say the HypoSpray® technology leaps past the state of the art and will enable delivery of compounds and classes of drugs not possible with patches. This has the potential to revolutionize medicine and I am very pleased to be a part of it.”
About Transdermal Delivery Solutions (TDSC)
TDSC is committed to advancing the science of transdermal drug delivery using its patented spray-on delivery system platform, HypoSpray®. TDSC’s proprietary system enables a much larger number of medications to be delivered directly through the skin, for systemic or localized application, utilizing its rapid acting, patchless, spray-on technology. TDSC’s technology represents a paradigm-shift in drug delivery. http://www.tdsc.us/lower.php?url=tdsc-platform
